Free Trial
TSE:HLS

HLS Therapeutics (HLS) Stock Price, News & Analysis

HLS Therapeutics logo
C$5.03 +0.03 (+0.60%)
As of 08/8/2025 03:29 PM Eastern

About HLS Therapeutics Stock (TSE:HLS)

Key Stats

Today's Range
C$5.03
C$5.10
50-Day Range
C$4.75
C$5.05
52-Week Range
C$3.00
C$5.45
Volume
2,207 shs
Average Volume
12,906 shs
Market Capitalization
C$111.91 million
P/E Ratio
N/A
Dividend Yield
3.98%
Price Target
C$4.50
Consensus Rating
Hold

Company Overview

HLS Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
16th Percentile Overall Score

HLS MarketRank™: 

HLS Therapeutics scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    HLS Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    HLS Therapeutics has received no research coverage in the past 90 days.

  • Read more about HLS Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of HLS Therapeutics is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of HLS Therapeutics is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    HLS Therapeutics has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for HLS.
  • Dividend Leadership

    HLS Therapeutics is a leading dividend payer. It pays a dividend yield of 4.30%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    HLS Therapeutics does not have a long track record of dividend growth.

  • Read more about HLS Therapeutics' dividend.
  • Short Interest

    There is no current short interest data available for HLS.
  • News Sentiment

    HLS Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for HLS Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, HLS Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$495.00 in company stock and sold C$0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.37% of the stock of HLS Therapeutics is held by insiders.

  • Percentage Held by Institutions

    65.20% of the stock of HLS Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about HLS Therapeutics' insider trading history.
Receive HLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HLS Stock News Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
HLS Therapeutics Reports Annual Meeting Results
HLS Therapeutics Announces Q1 2025 Financial Results
See More Headlines

HLS Stock Analysis - Frequently Asked Questions

HLS Therapeutics' stock was trading at C$3.93 at the beginning of the year. Since then, HLS stock has increased by 28.0% and is now trading at C$5.03.

HLS Therapeutics Inc. (TSE:HLS) issued its earnings results on Thursday, November, 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. HLS Therapeutics had a negative trailing twelve-month return on equity of 25.27% and a negative net margin of 38.70%.
Read the conference call transcript
.

Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that HLS Therapeutics investors own include Toronto-Dominion Bank (TD), Meta Platforms (META), NVIDIA (NVDA), CohBar (CWBR), Alphabet (GOOG), Great-West Lifeco (GWO) and ObsEva (OBSV).

Company Calendar

Last Earnings
11/07/2024
Today
8/09/2025

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
TSE:HLS
CIK
N/A
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

High Price Target
C$5.00
Low Price Target
C$4.00
Potential Upside/Downside
-10.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
C($1.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-C$15.53 million
Net Margins
-38.70%
Pretax Margin
N/A
Return on Equity
-25.27%
Return on Assets
-2.89%

Debt

Debt-to-Equity Ratio
86.50
Current Ratio
1.56
Quick Ratio
1.01

Sales & Book Value

Annual Sales
C$40.13 million
Price / Sales
2.79
Cash Flow
C$0.33 per share
Price / Cash Flow
15.22
Book Value
C$2.51 per share
Price / Book
2.00

Miscellaneous

Outstanding Shares
22,247,717
Free Float
N/A
Market Cap
C$111.91 million
Optionable
Not Optionable
Beta
1.07
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (TSE:HLS) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners